aTyr Pharma Newsroom

Analysts' Top Healthcare Picks: ATyr Pharma (LIFE), Dynavax (DVAX)

TipRanksMay 14 22:20

ATyr Pharma Says DSMB Recommended Ongoing Phase 3 EFZO-FIT Study Of Efzofitimod Continue Without Any Modifications

ATyr Pharma Says DSMB Recommended Ongoing Phase 3 EFZO-FIT Study Of Efzofitimod Continue Without Any Modifications

BenzingaMay 14 20:18

ATyr Pharma to Present at Upcoming Investor Conferences

SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its pro

GlobeNewswireMay 6 20:00

HC Wainwright & Co. : The ATyr Pharma (LIFE.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $35.00.

HC Wainwright & Co. : The ATyr Pharma (LIFE.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $35.00.

Zhitong FinanceMay 4 04:01

RBC Capital Sticks to Their Buy Rating for ATyr Pharma (LIFE)

TipRanksMay 3 19:06

Strong Buy Rating for ATyr Pharma as Efzofitimod Shows Promise and Financial Stability

TipRanksMay 3 18:26

ATyr Pharma Q1 EPS $(0.23) Beats $(0.24) Estimate, Sales $235.00K Beat $20.00K Estimate

aTyr Pharma (NASDAQ:LIFE) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.24) by 4.17 percent. This is a 20.69 percent increase over losses of $(0.29) p

BenzingaMay 3 04:27

Earnings Flash (LIFE) ATYR PHARMA Reports Q1 Revenue $235,000

04:00 PM EDT, 05/02/2024 (MT Newswires) -- Earnings Flash (LIFE) ATYR PHARMA Reports Q1 Revenue $235,000

MT NewswiresMay 3 04:00

ATyr Pharma 1Q Loss/Shr 23c >LIFE

ATyr Pharma 1Q Loss/Shr 23c >LIFE

Dow JonesMay 3 04:00

12 Health Care Stocks Moving In Tuesday's After-Market Session

GainersJaguar Health (NASDAQ:JAGX) shares rose 25.3% to $0.11 during Tuesday's after-market session. The company's market cap stands at $31.1 million. aTyr Pharma (NASDAQ:LIFE) shares rose 10.45% to $

BenzingaApr 10 04:31

ATyr Pharma to Participate in April Investor Conferences

SAN DIEGO, April 01, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its p

GlobeNewswireApr 1 20:00

WW, ATNM and XTIA Are Among Pre Market Gainers

Seeking AlphaMar 19 20:04

Repligen Appoints Maggie A. Pax to Board of Directors

Yahoo FinanceMar 19 19:30

ATyr Pharma Full Year 2023 Earnings: Revenues Disappoint

Yahoo FinanceMar 16 20:56

ATyr Pharma Is Maintained at Outperform by RBC Capital

ATyr Pharma Is Maintained at Outperform by RBC Capital

Dow JonesMar 16 00:59

RBC Capital Maintains Outperform on ATyr Pharma, Lowers Price Target to $16

RBC Capital analyst Gregory Renza maintains aTyr Pharma (NASDAQ:LIFE) with a Outperform and lowers the price target from $19 to $16.

BenzingaMar 16 00:49

ATyr Pharma Inc (LIFE) Reports Full Year 2023 Financial Results and Corporate Progress

Yahoo FinanceMar 15 23:01

Analysts Offer Insights on Healthcare Companies: ATyr Pharma (LIFE), Conmed (CNMD) and Ascendis Pharma (ASND)

TipRanksMar 15 18:50

Buy Rating Affirmed for ATyr Pharma as Lead Candidate Efzofitimod Advances in Clinical Trials With Solid Financial Footing

TipRanksMar 15 18:25

Earnings Call Summary | ATyr Pharma(LIFE.US) Q4 2023 Earnings Conference

The following is a summary of the ATyr Pharma, Inc. (LIFE) Q4 2023 Earnings Call Transcript:Financial Performance:ATyr Pharma ended 2023 with $101.7 million in cash, restricted cash, cash equivalents,

Futu NewsMar 15 13:27 · Conference Call